AVANIR Pharmaceuticals
AVANIR Announces Positive Outcome of Zenvia PK Study
Published in Medical Patent Business Week, June 13th, 2008
AVANIR Pharmaceuticals (NASDAQ:AVNR) reported a positive outcome of its large, formal pharmacokinetic (PK) study of its investigational drug Zenvia(TM) (dextromethorphan/quinidine (DM/Q)). The objective of the formal PK study was to support identification of an alternative dosing formulation of Zenvia designed to deliver similar efficacy as observed in the first Phase III clinical study in diabetic peripheral neuropathic (DPN) pain but with an improved safety and tolerability profile. The study achieved its goal of identifying a new Zenvia dosing regimen that provides a similar pharmacokinetic profile of the dextromethorphan component, an improved adverse event profile and a lower overall...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Business Week
More Articles from Medical Patent Business Week
- Adduci, Mastriani & Schaumberg, Llp
International Trade Law Firm Adduci, Mastriani & Schaumberg Continues Expansion - American Security Resources Corporation
American Hydrogen Corp. Not In Default; Working on Joint Ventures for Major Developments - Angioplasty
Scientists at University of Arizona publish research in angioplasty - Aphios Corporation
Aphios Corporation Awarded Japanese Patent for Phospholipid Nanosomes Technology Platform - Aviva USA
Aviva USA Awarded Patent Related to Fixed Indexed Life Insurance - Cabinet NG, Inc.
Cabinet NG Unveils Innovations for Document Management Integration at ''Collaborate 2008'' User Conference - More from this issue of Medical Patent Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
